Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)

Journal of the Peripheral Nervous System

Volumn 18, Issue 2, 2013, Pages 141-152

  Niknami, Marzieh ^a   Wang, Min Xia ^a   Nguyen, Toan ^a   Pollard, John D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

experimental autoimmune neuritis; Fc receptor; intravenous immunoglobulin; stradomer

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; MYELIN; STRADOMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ELECTROPHYSIOLOGY; EVOKED SOMATOSENSORY RESPONSE; FEMALE; LATENT PERIOD; LEWIS RAT; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; NEURITIS; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SCIATIC NERVE; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PROTEIN MULTIMERIZATION; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS;

EID: 84879385142     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12022     Document Type: Article

References (48)

1. Aloulou M, Mkaddem SB, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, Benhamou M, Crestani B, Zhu Z, Blank U, Launay P, Monteiro RC, (2012). IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood 119: 3084-3096.
2. Augener W, Friedmann B, Brittinger G, (1985). Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut 50: 249-252.
3. Bazin R, Lemieux R, Tremblay T, St-Amour I, (2004). Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 127: 90-96.
4. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH, (1996). Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 19: 388-391.
5. Clynes R, (2007). Protective mechanisms of IVIG. Curr Opin Immunol 19: 646-651.
6. Crow AR, Song S, Siragam V, Lazarus AH, (2006). Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47: 710-713.
7. Czernik A, Toosi S, Bystryn JC, Grando SA, (2012). IVIg in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 45: 111-118.
8. Dalakas MC, (2004). The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102: 177-193.
9. Deng R, Balthasar JP, (2007). Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 109: 2470-2476.
10. Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM, Dhodapkar MV, (2007). Selective blockade of the inhibitory Fcgamma receptor (Fc gamma RIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204: 1359-1369.
11. Enders U, Toyka KV, Hartung HP, Gold R, (1997). Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol 76: 112-116.
12. Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD, (2005). Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med 5: 135-140.
13. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA, (1997). Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120: 1533-1540.
14. Harvey GK, Pollard JD, (1992). Patterns of conduction impairment in experimental allergic neuritis. An electrophysiological and histological study. J Neurol Neurosurg Psychiatry 55: 909-915.
15. Heininger K, Schafer B, Hartung HP, Fierz W, Linington C, Toyka KV, (1988). The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Ann Neurol 23: 326-331.
16. Jacob S, Rajabally YA, (2009). Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 7: 337-342.
17. Jain A, Olsen HS, Vyzasatya R, Burch E, Sakoda Y, Merigeon EY, Cai L, Lu C, Tan M, Tamada K, Schulze D, Block DS, Strome SE, (2012). Fully recombinant IgG2a Fc multimers (stradomersTM) effectively treat collagen induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther 14: R192.
18. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J Peripher Nerv Syst 15: 1-9.
19. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV, (2006). Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203: 789-797.
20. Karsten CM, Köhl J, (2012). The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217: 1067-1079.
21. Kotlan B, Stroncek DF, Marincola FM, Kotlan B, Stroncek DF, Marincola FM, (2009). Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy 1: 995-1015.
22. Lin HH, Wang MX, Spies JM, Pollard JD, (2007). Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin. J Neuroimmunol 186: 133-140.
23. Ling ZD, Ziltener HJ, Webb BT, Matheson DS, (1990). Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol 129: 95-103.
24. Lisi S, Sisto M, Lofrumento DD, D'Amore S, D'Amore M, (2011). Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake. Clin Exp Med 11: 1-10.
25. Maurer M, Toyka KV, Gold R, Maurer M, Toyka KV, Gold R, (2002). Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 12: 405-414.
26. Miyagi F, Horiuchi H, Nagata I, Kitahara S, Kiyoki M, Komoriya K, Yuki N, (1997). Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 78: 127-131.
27. Morgan EL, Tempelis CH, (1978). The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression. J Immunol 120: 1669-1671.
28. National Blood Authority Australia (2010). Report on the use of Intravenous Immunoglobulin (IVIg) for 2009-2010.
29. Nimmerjahn F, Lunemann JD, (2011). Expression and function of the inhibitory Fc gamma-receptor in CIDP. J Peripher Nerv Syst 16: 41-44.
30. Nimmerjahn F, Ravetch JV, (2006). Fc gamma receptors: old friends and new family members. Immunity 24: 19-28.
31. Nimmerjahn F, Ravetch JV, (2007). The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204: 11-15.
32. Nimmerjahn F, Ravetch JV, (2008). Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
33. Nobile-Orazio E, Gallia F, Tuccillo F, Terenghi F, (2010). Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr Opin Neurol 23: 519-523.
34. Norton WT, Poduslo SE, (1973). Myelination in rat brain: method of myelin isolation. J Neurochem 21: 749-757.
35. Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL, (2010). IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 229: 256-262.
36. Ramakrishna C, Newo ANS, Shen YW, Cantin E, (2011). Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 7: e1002071.
37. Samuelsson A, Towers TL, Ravetch JV, (2001). Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
38. Sewell WAC, Jolles S, (2002). Immunomodulatory action of intravenous immunoglobulin. Immunology 107: 387-393.
39. Shahrizaila N, Yuki N, (2011). The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opin Pharmacother 12: 1551-1560.
40. Siberil S, Elluru S, Negi VS, Ephrem A, Misra N, Delignat S, Bayary J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV, (2007). Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 37: 103-107.
41. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH, (2005). Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 115: 155-160.
42. Spies JM, Pollard JD, Bonner JG, Westland KW, McLeod JG, (1995). Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol 57: 77-84.
43. Tackenberg B, Jeli I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lunemann JD, (2009). Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 106: 4788-4792.
44. Tackenberg B, Nimmerjahn F, Lunemann JD, Tackenberg B, Nimmerjahn F, Lunemann JD, (2010). Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 30 (Suppl 1): S65-S69.
45. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK, (2001). Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98: 1095-1099.
46. Tournadre A, Dubost JJ, Soubrier M, (2010). Treatment of inflammatory muscle disease in adults. Joint Bone Spine 77: 390-394.
47. Wietholter H, Hulser PJ, (1985). Lumbar-spinal somatosensory evoked potentials in the rat after stimulation of the tibial nerve. Exp Neurol 89: 24-31.
48. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr, (2011). Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res 11: 101.